Automated radiosynthesis of [ 11 C]MTP38-a phosphodiesterase 7 imaging tracer-using [ 11 C]hydrogen cyanide for clinical applications.

Autor: Kawamura K; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan., Hashimoto H; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan., Ohkubo T; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; SHI Accelerator Service Ltd., Tokyo, Japan., Hanyu M; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan., Ogawa M; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; SHI Accelerator Service Ltd., Tokyo, Japan., Nengaki N; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; SHI Accelerator Service Ltd., Tokyo, Japan., Arashi D; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; Tokyo Nuclear Services Ltd., Tokyo, Japan., Kurihara Y; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; SHI Accelerator Service Ltd., Tokyo, Japan., Fujishiro T; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; Tokyo Nuclear Services Ltd., Tokyo, Japan., Togashi T; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; Tokyo Nuclear Services Ltd., Tokyo, Japan., Sakai T; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; Tokyo Nuclear Services Ltd., Tokyo, Japan., Muto M; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.; Tokyo Nuclear Services Ltd., Tokyo, Japan., Takei M; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan., Ishii H; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan., Saijo T; Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan., Matsumura T; Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan., Obokata N; Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan., Zhang MR; Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Jazyk: angličtina
Zdroj: Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2022 May 15; Vol. 65 (5), pp. 140-146. Date of Electronic Publication: 2022 Feb 09.
DOI: 10.1002/jlcr.3965
Abstrakt: We have developed 8-amino-3-(2S,5R-dimethyl-1-piperidyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-[ 11 C]carbonitrile ([ 11 C]MTP38) as a positron emission tomography (PET) tracer for the imaging of phosphodiesterase 7. For the fully automated production of [ 11 C]MTP38 routinely and efficiently for clinical applications, we determined the radiosynthesis procedure of [ 11 C]MTP38 using [ 11 C]hydrogen cyanide ([ 11 C]HCN) as a PET radiopharmaceutical. Radiosynthesis of [ 11 C]MTP38 was performed using an automated 11 C-labeling synthesizer developed in-house within 40 min after the end of irradiation. [ 11 C]MTP38 was obtained with a relatively high radiochemical yield (33 ± 5.5% based on [ 11 C]CO 2 at the end of irradiation, decay-corrected, n = 15), radiochemical purity (>97%, n = 15), and molar activity (47 ± 12 GBq/μmol at the end of synthesis, n = 15). All the results of the quality control (QC) testing for the [ 11 C]MTP38 injection complied with our in-house QC and quality assurance specifications. We successfully automated the radiosynthesis of [ 11 C]MTP38 for clinical applications using an 11 C-labeling synthesizer and sterile isolator. Taken together, this protocol provides a new radiopharmaceutical [ 11 C]MTP38 suitable for clinical applications.
(© 2022 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje